Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Net revenue:
Total net revenue	[1]	$ 102,562	$ 99,548	$ 285,353	$ 287,951
Cost of revenue:
Total cost of revenue	[2]	63,020	60,415	169,577	177,975
Gross profit		39,542	39,133	115,776	109,976
Operating expenses:
Research and development	[3]	13,268	11,164	37,372	37,569
Selling and marketing		10,567	11,106	29,813	35,699
General and administrative		11,281	8,894	30,498	29,396
Total operating expenses		35,116	31,164	97,683	102,664
Income from operations		4,426	7,969	18,093	7,312
Income (loss) on equity method investment, net		(68)	222	1,021	222
Other (expense) income, net		(4,027)	(5,281)	(12,981)	(1,954)
Income before provision for income taxes		331	2,910	6,133	5,580
Provision for income taxes		721	285	1,352	1,601
Net income (loss)		$ (390)	$ 2,625	$ 4,781	$ 3,979
Net income (loss) per share - basic		$ 0.00	$ 0.03	$ 0.05	$ 0.04
Net income (loss) per share - diluted		$ 0.00	$ 0.03	$ 0.05	$ 0.04
Weighted average common shares used in computing net income per share:
Basic		93,123	90,476	92,106	89,585
Diluted		93,123	90,855	93,422	90,429
Net income		$ (390)	$ 2,625	$ 4,781	$ 3,979
Foreign currency translation adjustment		(2,102)	(628)	1,199	(769)
Comprehensive income (loss)		(2,492)	1,997	5,980	3,210
Products
Net revenue:
Total net revenue		47,439	45,527	120,502	126,892
Cost of revenue:
Total cost of revenue		27,709	27,573	69,237	73,661
Services
Net revenue:
Total net revenue		55,123	54,021	164,851	161,059
Cost of revenue:
Total cost of revenue		$ 35,311	$ 32,842	$ 100,340	$ 104,314

[1] Includes sales to the China joint venture, an equity method investment of $6,568 and $16,151 for the three and nine months ended March 31, 2021 and $6,145 and $12,605 for the three and nine months ended March 31, 2020, respectively. See Note 14.

[2] Includes cost of revenue from sales to the China joint venture, an equity method investment of $2,387 and $7,088 for the three and nine months ended March 31, 2021, respectively, and of $4,350 and $8,980 for the three and nine months ended March 31, 2020, respectively.

[3] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $0 and $430 for the three and nine months ended March 31, 2021, respectively, and no chargeback for the three and nine months ended March 31, 2020.